Re-inventing adherence: Patient-centered care for drug-resistant TB/HIV

MARCH 19 & 20, 2015
AGENDA

DAY 1: MARCH 19, 2015

8:00 - 8:30  BREAKFAST

8:30 - 8:35  WELCOME ADDRESS

Wafaa El-Sadr, MD, MPH, MPA
ICAP, Columbia University

8:35 - 8:45  SYMPOSIUM INTRODUCTION

Max O’Donnell, MD, MPH
Columbia University

8:45 - 9:30  FRAMING THE PROBLEM: ADHERENCE AND PATIENT-CENTERED CARE IN DR-TB/HIV

Salmaan Keshavjee, MD, PhD, ScM
Partners in Health, Harvard Medical School

9:30 - 10:45  PREFERENTIAL ADHERENCE TO ART OVER DR-TB TREATMENT

Max O’Donnell, MD, MPH
Columbia University

DISCUSSANT  David Bangsberg, MD, MPH
Harvard Medical School

CARING FOR THE CO-INFECTED: SOCIAL AND ETHICAL CONSIDERATIONS IN DR-TB/HIV

Amrita Daftary, PhD, MPH
University of Toronto

DISCUSSANT  Rivet Amico, PhD
University of Michigan

DECENTRALIZATION OF TREATMENT: A NEW DEFINITION FOR DOT?

Gerald Friedland, MD
Yale University School of Medicine

DISCUSSANT  Ernesto Jaramillo, MD, PhD
World Health Organization

10:45 - 11:00  COFFEE
# AGENDA

## Session 2: Challenging adherence

### 11:00 - 12:00

**PANEL DISCUSSION: DR-TB/HIV AS A SOCIOMEDICAL DISEASE: CONSTRUCTING THE CASCADE OF CARE**

**CO-CHAIR**
- Amrita Daftary, PhD, MPH
  - University of Toronto

**CO-CHAIR**
- Nesri Padayatchi, MD, MS
  - Center for AIDS Programme of Research in South Africa (CAPRISA)

**PANELISTS**
- Annika Sweetland, DrPH, MSW
  - Columbia University
- James Brust, MD
  - Montefiore, Albert Einstein College of Medicine
- Yael Hirsch-Moverman, PhD, MS, MPH
  - ICAP, Columbia University
- Jennifer Zelnick, ScD, MSW
  - Touro College

### 12:00 – 1:00

**LUNCH**

### 1:00 – 2:00

**WHO PERSPECTIVE ON PATIENT-CENTERED CARE IN DR-TB**

**Discussant**
- Salmaan Keshavjee, MD, PhD
  - Partners in Health, Harvard Medical School

### 3:00 - 3:15

**COFFEE**

## Session 3: Enhancing adherence

### 3:15 - 5:00

**INNOVATIVE TECHNOLOGIES TO MEASURE ADHERENCE**

**David Bangsberg, MD, MPH**
- Harvard Medical School

**John Metcalf, MD, MPH, PhD**
- University of California, San Francisco

**LESSONS LEARNT FROM HIV**

**Wafaa El-Sadr, MD, MPH, MPA**
- ICAP, Columbia University

**Gerald Friedland, MD**
- Yale University School of Medicine

**IMPLEMENTATION SCIENCE**

**Andrea Howard, MD, MS**
- ICAP, Columbia University

**Petros Isaakidis, MD, PhD**
- Médecins Sans Frontières

### 5:00

**CONCLUSION**

**Nesri Padayatchi, MD, MS**
- Center for AIDS Programme of Research in South Africa (CAPRISA)
## AGENDA

### DAY 2: MARCH 20, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 8:30</td>
<td>BREAKFAST</td>
</tr>
<tr>
<td>8:30 – 9:30</td>
<td><strong>Session 4: Synthesis of Day 1 and steps forward</strong></td>
</tr>
<tr>
<td></td>
<td><strong>SYNTHESIS OF ADHERENCE RESEARCH PRESENTATIONS</strong></td>
</tr>
<tr>
<td></td>
<td>Max O’Donnell, MD, MPH</td>
</tr>
<tr>
<td></td>
<td>Columbia University</td>
</tr>
<tr>
<td></td>
<td><strong>SYNTHESIS OF CASCADE OF CARE PANEL</strong></td>
</tr>
<tr>
<td></td>
<td>Nesri Padayatchi, MD, MS</td>
</tr>
<tr>
<td></td>
<td>Center for AIDS PRogramme of Research in South Africa (CAPRISA)</td>
</tr>
<tr>
<td></td>
<td>Amrita Daftary, PhD, MPH</td>
</tr>
<tr>
<td></td>
<td>University of Toronto</td>
</tr>
<tr>
<td></td>
<td><strong>SYNTHESIS OF ACTIVIST PANEL</strong></td>
</tr>
<tr>
<td></td>
<td>Mike Frick, MSc</td>
</tr>
<tr>
<td></td>
<td>Treatment Action Group</td>
</tr>
<tr>
<td>9:30 – 12:00</td>
<td><strong>ROUNDTABLE DISCUSSION: THE WAY FORWARD FOR PATIENTS</strong></td>
</tr>
<tr>
<td>12:00 - 1:00</td>
<td>LUNCH</td>
</tr>
<tr>
<td>1:00 - 2:00</td>
<td><strong>PRESENTATION OF RESEARCH AND IMPLEMENTATION AGENDA</strong></td>
</tr>
</tbody>
</table>
PARTICIPANTS

K RIVET AMICO, PHD
Research Associate Professor, University of Michigan, School of Public Health, Department of Health Behavior and Health Education

DAVID BANGSBERG, MD, MPH
Director of Global Health, Massachusetts General Hospital
Professor, Harvard Medical School, Harvard School of Public Health, and Mbarara University of Science and Technology

Dr. Amico is a research associate professor in the school of public health at the University of Michigan. Her program of research for the last 15 years has focused on social behavioral factors influencing HIV prevention and treatment. She has over 80 publications in these areas. She has contributed to practice guidelines and recommendations and to the evidence-base for assessment methodologies and design of trials targeting adherence and retention in care. As a counseling psychologist, Dr. Amico’s work focuses on the interface between biomedical advances and the social, structural, and individual factors that influence uptake, adherence and best outcomes.

Dr. Bangsberg completed medical school at Johns Hopkins, internal medicine and chief residency at Columbia Presbyterian Hospital, and Fellowships in Infectious Disease and AIDS Prevention at the University of California, San Francisco. He also holds Master’s Degrees in Public Health from the University of California, Berkeley and the History and Philosophy of Science from Kings College. Dr. Bangsberg has published over 320 manuscripts related to the study of social, behavioral, and structural determinants of HIV treatment in vulnerable populations.
Dr. Brust is an Assistant Professor of Medicine at Montefiore Medical Center and Albert Einstein College of Medicine where he holds joint appointments in the Divisions of General Internal Medicine and Infectious Diseases. His research has been focused on the province of KwaZulu-Natal, South Africa—an area with some of the highest rates of TB and HIV anywhere in the world. With a particular interest in TB drug resistance, he has spent the past 11 years studying TB/HIV co-infection, examining the epidemiology, transmission, and operational responses to the drug-resistant TB epidemic in the province.

Dr. Amrita Daftary is a Lecturer at the University of Toronto with expertise in socio-behavioural research and qualitative methods. Amrita is committed to highlighting the patient’s voice to develop socially informed and socially responsive approaches to HIV and TB care. She has studied the social challenges of drug-resistant TB in sub-Saharan Africa since 2005. She shares close affiliations with the CIHR Social Research Centre in HIV Prevention in Toronto, CAPRISA in South Africa, and ICAP at Columbia University. Amrita has an MPH in health promotion, PhD in social and behavioural sciences, and works as a community pharmacist in Toronto.
Dr. El-Sadr leads the Global Health Initiative at the Mailman School of Public Health. Dr. El-Sadr’s interests include: HIV/AIDS, tuberculosis maternal/child health, capacity building and health systems strengthening. Her work bridges interest and commitment to local and global public health challenges and an appreciation of the breadth of issues needed to transform the health of populations. She has extensive research experience and leads the NIH-funded HIV Prevention Trials Network.

Through ICAP, the center she established more than a decade ago, she has led the efforts that enabled the establishment of large-scale programs in 20 countries in Africa and Asia that link research, education, training and practice with a focus on HIV, other public health threats and health system strengthening.

She received her medical degree from Cairo University in Egypt, a masters in public health from Columbia School of Public Health (in Epidemiology) and a masters in public administration from Harvard University’s Kennedy School of Government. Her scholarly work has appeared in leading scientific journals. She was named a MacArthur Fellow in 2008 and a member of the Institute of Medicine in 2009.

Mike Frick is the TB/HIV project officer at Treatment Action Group, an independent AIDS research and policy think tank fighting for better treatment, a vaccine and a cure for AIDS and its two major co-infections, tuberculosis and hepatitis C. Mike holds a bachelor’s degree in international studies and Chinese from Kenyon College and a master of science degree in global health and population from the Harvard School of Public Health.
Dr. Friedland has worked in clinical and epidemiologic research and care of people living with HIV, AIDS and TB since 1981. During the past decade this has included work in KwaZulu Natal, South Africa addressing issues in HIV/TB integration and MDR and XDR TB epidemiology, care and treatment. He is Professor of Medicine and Epidemiology and Public Health at the Yale School of Medicine and Adjunct Professor at the Mailman School of Public Health at Columbia.

Dr. Hirsch-Moverman has an MS in Operations Research from Columbia University’s School of Engineering and Applied Science and an MPH and PhD in epidemiology from Columbia’s MSPH. She has vast experience in conducting epidemiologic and implementation science research, specifically in designing, conducting, and analyzing interventions to improve adherence and retention in TB/HIV programs. She is co-investigator of two implementation science cluster randomized trials that evaluate interventions to improve TB/HIV adherence in Ethiopia and Lesotho. She was recently awarded an NIH Mentored Research Scientist Development Award to evaluate a community-based intervention for the prevention of childhood TB in Lesotho.
Dr. Howard is director of the Clinical and Training Unit at ICAP, where she oversees the design and implementation of clinical, laboratory, and training programs for the prevention, care, and treatment of HIV, tuberculosis, and related conditions in resource-limited settings in sub-Saharan Africa and Asia. She is currently leading two cluster-randomized implementation science trials aimed at defining best practices for integrating TB and HIV service delivery programs in sub-Saharan Africa. Dr. Howard is an associate professor of epidemiology at Columbia University and director of the NIH-funded Global HIV Implementation Science Research Training Fellowship at Mailman School of Public Health.

Dr. Isaakidis is a medical epidemiologist and operational researcher. He has worked in Europe, sub-Saharan Africa, Middle East, South and South-East Asia, mostly with Médecins Sans Frontières (MSF)/Doctors Without Borders. Over the last 10 years he supported large-scale HIV and Tuberculosis and Drug-resistant Tuberculosis projects as coordinator and epidemiologist. Since 2012 he has been facilitating Operational Research courses as part of the UNION/MSF/WHO SORT-IT initiative. His research interests include HIV, DR-TB, co-infections and humanitarian and global health.
The drug-resistance policy task manager at the Global TB Programme of the World Health Organization is a Colombian medical doctor (1990, Universidad del Valle, Colombia), PhD in Health Education (1998, University of London, London, UK). His professional career in TB began delivering clinical care and programmatic management of TB and MDR-TB at dispensary level in the slums of his country, and continued with operational and social science research in TB care and control. Global policy on MDR-TB prevention, care and control has been at the centre of his work in the last sixteen years; twelve of them at the WHO Global TB Programme. While in WHO he has been the chief editor of the last two editions of the the WHO Guidelines for the treatment of MDR-TB, and has published in the field.

Dr. Keshavjee completed his medical training (MD) at Stanford University in 2001, after which he completed a clinician-scientist residency in Internal Medicine at Brigham and Women's Hospital. Since then his clinical research has focused on drug-resistant tuberculosis treatment. He has worked extensively with the Boston-based non-profit Partners In Health (PIH) on the treatment of drug-resistant tuberculosis. Over the last 14 years has conducted clinical and implementation research in Russia (2000-present). He was also the Deputy-Director for the PIH Lesotho Initiative (2006-2008), launching one of the first community-based treatment programs for multi-drug resistant tuberculosis/HIV co-infection in sub-Saharan Africa. His research has resulted in a number of manuscripts of global clinical and policy significance.

Dr. Keshavjee has been very involved in global policy discussions around the treatment of drug-resistant tuberculosis. In 2005, he became a member of the World Health Organization/Stop TB Partnership’s Green Light Committee for MDR-TB Treatment. From 2007 to 2010, he was the committee’s chair. He has spent considerable time working on alternate mechanisms for drug procurement, technical assistance delivery, and program implementation. In addition to acting as a consultant to a number of projects globally, Dr. Keshavjee was the co-author of an Institute of Medicine white paper on overcoming barriers to expanding treatment for MDR-TB. Dr. Keshavjee is leading an initiative at Harvard Medical School on how to achieve zero deaths from tuberculosis.
Dr. Metcalfe completed his medical residency and fellowship training at the University of California, San Francisco (UCSF). He then completed a PhD in epidemiology from the University of California, Berkeley. He is an Assistant Professor in the Division of Pulmonary and Critical Care Medicine at UCSF. His research interests focus on the diagnosis, management, and transmission of drug-resistant tuberculosis, domestically and in high HIV-burden settings. He holds an honorary lectureship position at the University of Zimbabwe College of Health Sciences.

As director of Treatment Action Group’s TB/HIV Project, Erica works with activists, developers, donors and policymakers to accelerate research and ensure it reflects input from affected communities, and to expand access to evidence-based strategies to fight TB and TB/HIV.

Erica has worked at the TB Alliance, with the CDC’s National HIV Behavior Surveillance System in Baltimore, and was an Urban Fellow at the NYC Department of Health. She supported efforts to combat sex trafficking in South Asia, and started the Republic of Georgia’s first breast cancer peer support program.

Erica received her MPH as a Sommer Scholar at the Johns Hopkins Bloomberg School of Public Health. She has a BA in Spanish and Psychology from Georgetown.

---

ERICA LESSEM, MPH
Director, TB/HIV Project, Treatment Action Group

JOHN METCALFE, MD, MPH, PhD
Assistant Professor, Division of Pulmonary and Critical Care Medicine, University of California, San Francisco

As director of Treatment Action Group’s TB/HIV Project, Erica works with activists, developers, donors and policymakers to accelerate research and ensure it reflects input from affected communities, and to expand access to evidence-based strategies to fight TB and TB/HIV.

Erica has worked at the TB Alliance, with the CDC’s National HIV Behavior Surveillance System in Baltimore, and was an Urban Fellow at the NYC Department of Health. She supported efforts to combat sex trafficking in South Asia, and started the Republic of Georgia’s first breast cancer peer support program.

Erica received her MPH as a Sommer Scholar at the Johns Hopkins Bloomberg School of Public Health. She has a BA in Spanish and Psychology from Georgetown.
UVISTA NAIDOO, MBChB
Paediatric Registrar, University of Cape Town

Uvistra is a paediatric registrar at the University of Cape Town’s Red Cross War Memorial Children’s Hospital and George Hospital in South Africa. He is a medical graduate of the University of KwaZulu Natal. He began his medical career in Cape Town before having a substantial leave of absence due to ill health. Though still at a young age, his first hand experience with tuberculosis prompted him to devote his career toward fighting this dreaded disease. He is a Fogarty Global Infectious Diseases scholar and his main research interests include Mtb diagnostics and biomarker detection as well as understanding the mechanisms between malnutrition and TB, with emphasis in the child.

MAX O’DONNELL, MD, MPH
Assistant Professor of Medicine and Epidemiology, Columbia University Medical Center

Dr. O’Donnell is an academic pulmonologist and assistant professor of medicine and epidemiology at Columbia University Medical Center. His research interests range from laboratory-based biomarker discovery to clinical and qualitative research focused on the field of drug-resistant tuberculosis. His South African collaborators K-RITH and CAPRISA where he is a Research Associate. His clinical work includes working as a volunteer physician at a busy New York City tuberculosis clinic.
Dr. Padayatchi is the Deputy Director of CAPRISA at the University of KwaZulu-Natal in Durban. She is a lecturer in the Department of Community Medicine at the Nelson Mandela School of Medicine. She has more than 30 years clinical and research experience in the management of TB and related problems. She served as the South African Principal Investigator for the Columbia University-Southern African Fogarty AIDS International Training and Research Programme. She serves on the South African National and Provincial Advisory Board for MDR–TB. She is a member of ASSAf. She was the eThekwini Clinical Research Site leader from 2006 to 2013 as well as the CAPRISA Principal Investigator for ACTG.

Meera Senthilingam is a global health journalist, researcher and communications specialist. Through her Masters degree in Science Communication from Imperial College she reported on global health issues across the world for the BBC, Nature, New Scientist and now writes for CNN International and broadcasts on the BBC World Service. Her second Masters in the Control of Infectious Diseases from the LSHTM resulted in specializing in qualitative research with tuberculosis patients in South Africa with the Lung Infection and Immunity Unit at UCT. She has researched perspectives of XDR-TB patients who failed treatment and patient experiences of DOT in the Western Cape.
Jennifer Zelnick is an Associate Professor and Social Welfare Policy Chair at the Touro College Graduate School of Social Work. Her research focuses on the impact of drug-resistant TB and HIV on lives of health care workers in South Africa. She is the author of “Who is Nursing Them? It Is Us”: Neoliberalism, HIV/AIDS and the Occupational Health and Safety of South African Public Sector Nurses, and has conducted qualitative research on workplace safety and infection control in the context of drug-resistant TB. She collaborates with social work faculty in Durban, South Africa around social welfare policy and workforce issues.

Annika Sweetland, DrPH, MSW is Research Fellow in Global Mental Health at Columbia University and Co-Founder and Co-Chair of the TB and Mental Health Working Group at the International Union Against Tuberculosis and Lung Disease. Her research has focused on the integration of depression treatment in primary care in low resource settings, with a focus on TB and depression in Peru, Brazil, and Mozambique.